In the recent Korean study by Kim et al. which retrospectively analyzed the national insurance claims data of 39989 patients with T2DM, metformin use for >3 years was associated with a significant 43% reduction of gastric cancer risk among those who did not use insulin [43]. Here, INS is linked to gastric cancer.